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Here we investigated the role of NFAT-interacting protein (NIP)-45, an Interleukin (IL)-4 inducing 
Transcription Factor, and its impact on the differentiation of Group 2 Innate -Lymphoid -Cells (ILC2s) in 
the pathogenesis of asthma. NIP45, a transcription factor regulating NFATc1 activity, mRNA was found 
to be induced in the peripheral Blood mononuclear cells (pMBcs) of asthmatic pre-school children with 
allergies and in the peripheral blood CD4+ t cells from adult asthmatic patients. in pBMcs of asthmatic 
and control children, NIP45 mRNA directly correlated with NFATc1 but not with T-bet. Targeted deletion 
of NIP45 in mice resulted in a protective phenotype in experimental asthma with reduced airway mucus 
production, airway hyperresponsiveness and eosinophils. this phenotype was reversed by intranasal 
delivery of recombinant r-IL-33. Consistently, ILC2s and not GATA3+ CD4+ t-cells were decreased in 
the lungs of asthmatic NIP45−/− mice. Reduced cell number spleen ILC2s could be differentiated from 
NIP45−/− as compared to wild-type mice after in vivo injection of a microcircle-DnA vector expressing 
IL-25 and decreased cytokines and ILC2 markers in ILC2 differentiated from the bone marrow of 
NIP45−/− mice. NIP45 thus emerges as a new therapeutic target for the resolution of the airway 
pathology, down-regulation of ILC2s and mucus production in asthma.
Allergic asthma is a disease associated with reversible airway inflammation, airway hyperresponsiveness (AHR), 
mucus production and airway remodeling. All these features have been linked to an aberrant differentiation 
of T helper (h)2 cells that produce the cytokines IL-4, IL-5 and IL-131. Current treatments for allergic asthma 
are anti-inflammatory medications enclosing steroids2. Nuclear factor of activated T-cells(NFAT)-interacting 
protein (NIP)45 is a Th2 associated transcription factor known to potentiate Nuclear factor of activated T-cells 
(NFATc)2-driven interleukin (IL)-4 expression3. After T cell receptor antigen challenge, NFAT-interacting pro-
tein (NIP)-45 is methylated at its amino-terminal region by the protein arginine methyltransferase (PRMT1). The 
arginine methylation domain of NIP45 supports the interaction with nuclear factor of activated T cells (NFAT) 
and recruits PRMT1 to the NFAT transcription-activating complex, thereby enhancing the production of IL-44. 
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Moreover, NIP45 deficient mice have been shown to be deficient in IL-4 and IFN-γ production, indicating that 
NIP45 controls both Th1 and Th2 cytokine production3–5.
NFAT is a family of transcription factors that are known to be activated by calcium influx and consist of five 
family members (NFATc1, NFATc2, NFATc3, NFATc4 and NFAT5)6. In activated T cells, NFATc1 was first iden-
tified to control the IL-2 promoter7. Individual family members play different roles in T cell development and 
activation. Additionally, they also have effects on the regulation of numerous other immune cells8–11.
The different NFAT family members regulate Th1, Th2 and Th17 cells12. It has been previously shown that 
in the absence of NFATc2, the differentiation of Th1 cells is diminished, while the development of Th2 cells 
and IL-4 production is up-regulated, especially in a model of allergic asthma9,13. The loss of both NFATc2 and 
NFATc3 leads to increased expression of Th2 cytokines as well as to high IgG1 and IgE levels14–17. In contrast, we 
and others have demonstrated that the absence of NFATc1 in T cells, IL-4 and other Th2 cytokines as well as the 
levels of IgE and IgG1 production are reduced16,18,19. Thus the phenotype of NFAT deficient mice does not reflect 
differences in DNA-binding or transcriptional activity at the IL-4 promoter, but most likely indicates interactions 
with other regulating transcription factors or other indirect effects.
Therefore, we reasoned that NFAT regulating transcription factors like NIP45 may be involved in the regula-
tion of NFAT and thus in the development of allergic asthma1.
Innate lymphoid cells group 2 (ILC2) do not express lineage markers but share effector functions with Th2 
cells. They are a rare cell population that comprises a distinct lineage of IL, found to be increased after allergen 
treatment. They are able to develop type-2 immune responses20–23. ILC2s differentiate in the bone marrow from 
a common lymphoid precursor (CLP)24,25. It has been demonstrated that they express ST2, which is a receptor 
subunit of IL-33, IL-17RB, a receptor subunit of IL-25, and TSLPR, which is a component of the receptor for 
thymic stromal lymphopoietin21. Therefore, ILC2s are cells that respond to alarmin-like cytokines such as IL-33, 
IL-25 and thymic stromal lymphopoietin (TSLP) which are released by activated or damaged epithelial cells. 
Epithelial cells are the first barrier of defense against allergens and play a crucial role in the development of aller-
gic asthma26,27. Furthermore, ILC2s express the common γ-chain CD132, as well as CD25 and CD127. For the 
development and function of ILC2s the transcription factors GATA3 and RORα play essential roles. In the lungs, 
ILC2s have a critical role in inducing an innate type 2 immune response caused by inhaled allergens28,29. They are 
the primary source of the cytokines IL-5 and IL-13. Therefore they represent an important cell type in diseases 
mediated by type 2 immune responses, such as asthma and allergy22,28,30–32.
The aim of this study was to better understand the function of NIP45 in allergic asthma and its possible impact 
on the biological functions of ILC2s. We observed that NIP45−/− mice show decreased pathological characteris-
tics of asthma, like inflammation, AHR and mucus production, in two experimental asthma models after OVA 
and HDM challenge, respectively. Furthermore, we detected a defect in ILC2 survival and proliferation in the 
absence of NIP45 in allergic asthma and spleen derived ILC2s, indicating a crucial role for NIP45 in mediating 
asthma via ILC2.
Results
increased expression of Nip45 mRNA in asthmatic subjects positively correlated with NFATc1 
levels. In the context of the European Study PreDicta, we examined two cohorts of healthy and asthmatic 
pre-school children at the age of 4–6 years (Table S1). The expression of NIP45 mRNA in unstimulated PBMCs 
from these two cohorts of pre-school children was then analyzed. Here we observed that children with asthma 
expressed significantly higher NIP45 mRNA levels than healthy individuals (Fig. 1a,b and Table S1). In table S1 
also the medications taken by the children with asthma are reported. No relation was observed between patients 
taking steroids and those treated with non-steroid medication and NIP-45 expression. We next analyzed the 
expression of NIP45 in PBMCs from these asthmatic children with additional self-reported atopic eczema. 
NIP45 was found significantly induced in asthmatic pre-school children with self-reported atopic eczema and 
positive skin test (Fig. 1c,d, respectively), similarly to what we recently reported for NFATc1 expression in these 
cohorts of children. To confirm these findings, in a second cohort of subjects from the Asthma Bio-Repository for 
Integrative Genomic Exploration (ABRIDGE, Nasmathics = 300, Nhealthy = 122), we investigated the mRNA expres-
sion of NIP45 in peripheral blood CD4+ T cells. After adjustment for age, race, gender and batch effect, the 
average NIP45 mRNA expression was moderately higher among asthmatics than non-asthmatic controls (p for 
moderated t-statistics = 0.036, fold change = 1.04, Fig. 1e,f). These findings were consistent with the idea that 
NIP45 might have a role in asthma. Moreover, the increase in NIP45 seen in PBMCs of asthmatic children shows 
a ~5 fold expression difference, whereas in sorted CD4+ T cells this is only 1.04-fold. These findings are con-
sistent with a role of NIP45 expression in Th2 cells but also in other cell type present in the PBMCs of asthmatic 
children. Furthermore, we next asked about a correlation between the recently described increase of NFATc1 in 
the blood of children with asthma and NIP45. Therefore, we next analyzed the correlation between NIP45 and 
NFATc1 mRNA expression in the blood cells of these children and found a highly significant direct correlation 
between the expression levels of these two transcription factors both in healthy controls and in asthmatic children 
(Fig. 2a,b, respectively).
This direct correlation was not observed when NIP45 mRNA was correlated with T-bet, (Fig. 2c,d), another 
protein present on the promoter of IFN-gamma closely associated with NFATc123, mRNA extracted from the 
PBMCs of asthmatic and control children, indicating a specific role of Nip45 in association with NFATc1 in aller-
gic asthma (Fig. 2c,d).
NIP45 deficiency is associated with a reduced asthmatic phenotype. To explore the functional 
role of NIP45 in asthma, NIP45−/− mice and wild-type littermates were analyzed in an experimental model of 
allergic asthma induced by ovalbumin (OVA) sensitization alone and OVA sensitization and challenge (Fig. 3a).
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Lung histological sections were evaluated for peri-bronchial and perivascular inflammation as previously 
described33. Increased numbers of inflammatory cells were detected in the bronchi and peribronchial ves-
sels of OVA challenged wild-type but not in NIP45−/− mice (Fig. 3b). We also analyzed mice in a different 
genetic background (Balb/c) in naïve and OVA sensitized and challenged mice and confirmed the reduction of 
OVA-dependent AHR in the absence of NIP45 (Fig. 3c–e). In fact, OVA sensitized and OVA sensitized and chal-
lenges NIP45−/− mice revealed a significantly lower AHR as compared to the wild-type control asthmatic groups 
as measured both by PenH and airway resistance (Fig. 3d,e, respectively). We further assessed mucus production 
in the lungs of wild-type and NIP45−/− mice by PAS staining (Fig. 3f). OVA treatment induced mucus production 
in both, wild-type and NIP45−/− mice, but NIP45−/− mice showed significantly decreased number of PAS+ cells 
in this setting. Furthermore, we asked which kind of inflammatory cells where regulated by NIP45 in asthma. 
Eosinophils, which are significantly upregulated in the Bronchoalveolar lavage fluid (BALF) in asthma in wild 
type mice, where found to be significantly downregulated in the absence of NIP45 in asthma (Fig. 3g, left and 
middle panel). Residual Eosinophils remained in the airways in the absence of NIP45. The role of eosinophils in 
asthma has been revised to enclose resident eosinophils which play a resolving role in allergic asthma34. Further 
studies might address the possibility that NIP45 deficiency is associated with resident eosinophils. In addition, 
also neutrophils, a less represented inflammatory cell type in the airways of asthmatic mice, was also found inhib-
ited in the BALF in the absence of NIP45 in this model of asthma (Fig. 3g, left and right panel). Taken together, 
these results suggested that NIP45 plays a pathogenic role in allergic asthma by regulating airway inflammation, 
mucus production and airway hyperresponsiveness.
We next analyzed T-bet mRNA in the lung of naïve and asthmatic wild type and NIP45−/− mice. Here we 
found a downregulation of T-bet in the lung of naïve mice in the absence of NIP45(Fig. 4a). These results are 
consistent with a role of NIP45 on NFATc1 activitation on T-bet promoter23. In asthma, this effect was abol-
ished probably because other transcription factors might replace NFATc1 on T-bet promoter. Consistent with a 
reported role of NIP45 on Th13–5, targeted deletion of NIP45 resulted in absence of IFN-gamma in the airways 
(Fig. 4b). Consistent with T-bet, also IFN-gamma was reduced in naïve NIP45 deficient mice (Fig. 4b).
Figure 1. Increased expression of Nip45 in children with asthma. (a) Experimental design of PBMCs RNA 
isolation for qPCR from healthy and asthmatic children. (b–d) Relative mRNA expression for NIP45. n = 12–17 
children per group. (e,f) Differential NIP45 mRNA expression between asthmatics and healthy controls 
in Asthma BRIDGE study (p < 0.001 obtained from Wilcoxon rank sum test with continuity correction; 
N.healthy = 122, N.asthmathics = 300). Distribution of NIP45 mRNA expression among 422 subjects.
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We next reasoned that, GATA-3 is a Th2 transcription factor which has been demonstrated to orchestrate 
airway inflammation, mucus production and airway hyperresponsiveness35. We then asked if lung CD4+ T cells 
expressing GATA-3 were regulated by NIP45 but although we detected a significant induction of GATA3+ CD4+ T 
cells in the OVA sensitized and challenged mice as compared to PBS mice, no difference was observed between 
wild type and NIP45−/− mice (Fig. 4c).
NIP45 deficiency leads to down regulation of Th2 cytokines. Lymphocytes are a primary source 
of the type 2 cytokines IL-4, IL-5 and IL-13 which are upregulated in allergic asthma36. IL-4, a Th2 signature 
cytokine, was found significantly reduced in the supernatants of total lung cells isolated from naive and OVA 
treated NIP45−/− mice compared to the wild-type control groups (Fig. 5a). Similarly, the production of IL-5 was 
also reduced in NIP45−/− mice after sensitization and challenge with OVA compared to wild-type mice, while 
IL-5 protein was not detectable in total lung cells of untreated wild-type and NIP45−/− mice (Fig. 5b). Analysis 
of IL-13 levels also revealed a significant increase in wild-type and NIP45−/− mice after allergen sensitization and 
challenge. However, naive as well as asthmatic NIP45−/− mice showed significantly lower levels of IL-13 compared 
to wild-type control mice (Fig. 5c). Collectively, these data indicate that NIP45 controls the inducible production 
of key type 2 signature cytokines in allergic asthma.
NIP45−/− asthmatic mice show a decreased percentage of ILC2s after allergen sensitization 
and challenge. ILC2s are innate like cells that increase after exposure to allergen and are known to express 
ST2, a member of the IL-1 receptor family32. They are innate lymphocytes known to be important producers 
of IL-5 and IL-13 and seem to play a role in the pathogenesis of allergic asthma22,28,31. We next investigated the 
expression level of St2 mRNA in lung tissue from wild-type and NIP45−/− mice before and after allergen sensiti-
zation and challenge (Fig. 5d). We observed that St2 mRNA expression is significantly increased only in wild-type 
mice after induction of asthma. NIP45−/− mice showed significantly reduced expression levels of St2 mRNA in 
the OVA model compared to the wild-type littermates. We also investigated the number of Lin-Thy1.2+ cells 
in total lung cells. Thy1.2 (CD90.2) is a glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein 
involved in signal transduction and involved in co-stimulation of lymphocytes, all thymocytes, peripheral T cell 
proliferation and induction of hematopoietic stem cells differentiation37. Total lung Lin-Thy1.2+ cells were found 
downregulated in this model of asthma and not significantly regulated by NIP45 (Fig. 5e). We next analyzed 
Lin−ST2+ in total lung cells via flow cytometry and found that the number of these cells was increased in per-
centage but decreased in absolute number in asthmatic wild type mice and further significantly downregulated in 
asthmatic NIP45−/− mice (Fig. 5f). We further investigated ILC2s in the lungs of wild-type control and Nip45−/− 
mice. ILC2s defined as Lin−Thy1.2+KLRG1+ICOS+ cells (Fig. 5g) were significantly increased in percentage in 
Figure 2. NIP45 mRNA directly correlated with NFATc1 mRNA but not with T-bet mRNA in PBMCs of 
control and asthmatic pre-school children. (a,b) Linear regression analysis of qPCR analysis for NFATc1 and 
NIP45 mRNA corrected by HPRT mRNA expression of the cohorts of Predicta children described in panels 
a and b. Healthy controls n = 11, asthma n = 17. In the same children a correlation between NIP45 and T-bet 
mRNa was performed (c,d).
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OVA treated wild-type mice, while there was no significant induction in the absence of NIP45. When calculated 
as absolute number no differences among the groups were observed (Fig. S1a), similarly the gated non-ILC2 cells 
were induced in asthma in percentage in the lungs of naïve NIP45−/− mice and not regulated when the absolute 
number was considered (Fig. S1b).
Local administration of recombinant-rIL-33 reverses the protective asthmatic phenotype seen 
in NIP45−/− mice in a murine model of allergic asthma. To find out whether IL-33 is responsible for 
the decrease in Th2 cytokine production and pathological features in the lungs of asthmatic NIP45−/− mice, we 
treated the mice once with 1 µg of recombinant r-IL-33 intranasally, 30 minutes before the first in vivo challenge 
with OVA (Fig. 6a). Next, we investigated the impact of IL-33 on airway hyperresponsiveness and found that 
NIP45−/− mice intranasally treated with rIL-33 displayed a significant increase in the Penh value in response to 
methacholine compared to OVA alone, reaching Penh values comparable to the wild type asthmatic mice without 
exogenous rIL-33 (Fig. 6b). Next, we assessed the degree of inflammation in the lungs of the mice by H&E stain-
ing. We could observe that NIP45−/− asthmatic mice that additionally received rIL-33 intranasally show a signifi-
cant increase of inflammation compared to the OVA NIP45−/− group (Fig. 6c). Also, the wild type asthmatic mice 
had a significant induction of inflammation as compared to untreated wild type asthmatic mice (Fig. 6c). The 
same could be observed for the PAS staining of the lung sections: asthmatic NIP45−/− mice that were treated with 
rIL-33 had more PAS+ cells relative to bronchus size as compared to the NIP45−/− mice treated with OVA alone 
(Fig. 6d). Subsequently, we looked for the protein levels of the Th2 cytokines IL-4, IL-5 and IL-13 in total lung 
cells of NIP45−/− mice. We found that IL-4 was not upregulated by rIL-33, neither in wild type nor in NIP45−/− 
asthmatic mice (Fig. 6e). In addition, IL-5 but not IL-13 was further up-regulated in asthmatic NIP45−/− mice 
after exogenous administration of rIL-33 (Fig. 6f,g, respectively). Lastly, we investigated the mRNA expression 
Figure 3. Inhibition of the asthmatic phenotype in Nip45−/− mice in a murine model of allergic asthma. (a) 
Experimental design of the murine model of allergic asthma for the analysis of the invasive plethysmography 
and lung inflammation. (b) Histological sections of the lungs of non-asthmatic and asthmatic wild-type and 
Nip45−/− stained with H&E and corresponding pathological score of the inflammation. (c) Experimental 
design of the murine model of allergic asthma. (d) Airway resistance was analyzed with a non-invasive 
plethysmography as Penh and invasive method (e). (f) Periodic acid-Shiff (PAS) staining of lung sections of 
untreated and asthmatic Nip45−/− and wild-type control mice to show mucus producing cells in purple. (g) 
The percentage of eosinophils (Gr1+CCR3+) and neutrophils (Gr1+CCR3-) in BALF of allergen sensitized 
and challenged Nip45−/− and wild-type control mice were measured by flow cytometry. One representative 
experiment is shown with three to four mice per group. Students t-test was used to evaluate statistical 
significances. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Data are expressed as mean ± s.e.m.
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of St2 in the lungs of rIL-33 treated asthmatic Nip45−/− mice and found a significant upregulation after rIL-33 
treatment (Fig. 6h). Thus, these results demonstrate that the protective asthmatic phenotype seen in NIP45−/− 
mice seems to be dependent on rIL-33 and ILC2s, because the local administration of rIL-33 significantly induced 
AHR, inflammation, mucus production, IL-5 and St2 mRNA, the main characteristics of this disease.
NIP45 deficient mice have decreased AHR and produce less airway mucus in a model of house 
dust mite (HDM). Because house dust mites are an important trigger of allergic asthma in humans, we 
next employed a more physiological model of the disease and induced asthma in the airways of both wild-type 
and NIP45 deficient mice by intranasal challenge with HDM extract as illustrated in Fig. 7a. Given this model 
does not involve systemic sensitization, it particularly involves activation of cells of innate immunity like ILC2s. 
Consistently, we found a significant induction of ILC2 absolute cell number in the lungs of wild type asthmatic 
mice (Fig. 7b). Furthermore, consistent with our previous results in the OVA induced asthma, we found a reduc-
tion in the percentage (Fig. 7b) but not in the absolute number (Fig. S1c) of ILC2s in the airways of NIP45 
deficient mice. Moreover, mice deficient in NIP45 had decreased airway hyperresponsiveness (Fig. 7c) and less 
mucus production in the airways compared to the wild-type littermates in a model of allergic asthma (Fig. 7d). 
Here, GATA3, a signature transcription factor of Th2 cells and ILC2s, was downregulated in lung CD4+ T cells 
of HDM-treated NIP45−/− mice compared to wild-type control mice (Fig. 7e). Consistent with a role of NIP45 in 
the activation of the Il4 gene promoter, IL-4 was also found to be downregulated in the absence of NIP45 (Fig. 7f).
Reduced cell number and cytokine release in ILC2s differentiated from NIP45 deficient mice 
after in vivo enrichment with a minicircle DNA IL-25-expressing vector. We next asked the reason 
why we obtained less ILC2 differentiation in the absence of NIP45. To investigate this point we differentiated 
ILC2s both in wild type and in NIP45−/− mice after in vivo injection of a minicircle DNA vector expressing IL-25, 
a cytokine inducing ILC2s38.
We next analyzed mice treated with DNA vectors encoding for IL-25 and IL-33 and investigated subsets of 
ILC2s thoroughly. After 3 days, we sorted lung and splenic ILC2 cells Lin-ICOS+ KLRG1+ and cultured them 
under ILC2 differentiating conditions for 11 days (Fig. 8a,b). Here we observed that, inflammatory (i) ILC2s 
Figure 4. Decreased T-bet in the lung in the absence of NIP45. (a) T-bet mRNA was measured in the lung of 
wild type and NIP45−/− mice. (b) INF-gamma in total lung cell supernatants of wild type and NIP45 deficient 
mice. (c) Percentage of CD4+ GATA3+ T cells in the lungs of Nip45−/− and wild-type control mice analysed via 
flow cytometry. One representative of three independent experiments is shown with five to six mice per group. 
In this figure a Students t-test was used to evaluate statistical significances. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
Data are expressed as mean ± s.e.m.
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(lin− CD127+ KLRG1hi ST2−) were predominantely induced by IL-25, while natural (n) ILC2s (lin− CD127+ 
KLRG1int ST2+) preferentially increased upon IL-33 treatment in the Lung (Fig. 8a) as previously described39.
Then we set up a new experiment and analyzed the ILC2 after the injection of IL-25 DNA vector (Fig 8b). 
After 3 days we sorted lung and spleen Lin−ICOS+KLRG1+ILC2s and cultured them under ILC2 differentiat-
ing conditions for 11 days. During the cell growing period, we counted the spleen cells and found that at day 
8, the ILC2s obtained from NIP45−/− mice stopped growing (Fig. 8c). In addition, IL-4 was found significantly 
decreased in the absence of NIP45 in the cell supernatants of expanding ILC2s, at day 8 and day 11 (Fig. 8d). We 
next asked if NIP45 was expressed in ILC2s. To address this point, we measured NIP45 mRNA levels in the ILC2 
cultures derived from the wild type mice after in vitro ILC2s restimulation for 2 additional days with IL2 and IL-7, 
followed by re-stimulation for 24 hours with IL-2 (Fig. 8e). Here, we found a significant upregulation of NIP45 
mRNA as the ILC2s expanded in vitro (Fig. 8e). These data indicate a role of NIP45 in ILC2s. To further investi-
gate the mechanism on how NIP45 supports the survival of ILC2s, we reasoned that NIP45 deficient ILC2s are 
more likely to undergo apoptosis, a form of programmed cell death. To analyze this possibility, we performed an 
apoptosis assay with Annexin-V and Propidium Iodide (PI) (Fig. S2a). Here we found by trend an enhanced late 
apoptosis in the absence of NIP45 in the culture with IL-2 (Fig. S2a).
We next investigated the proliferation of the expanded and IL-2 re-stimulated ILC2s by using Ki67 staining 
and found a tendential proliferative defect in ILC2s in the absence of NIP45 (Fig. S2b). Furthermore, ILC2 differ-
entiated from NIP45 deficient mice produced less IL-13 and expressed less GATA3 as compared to those ILC2s 
isolated from the wild type littermates (Fig. S2c).
In conclusion, although further studies are required in this direction, NIP45 emerges as a new ILC2 marker 
involved in allergic asthma.
Decreased expression of ILC2 markers in bone marrow differentiated ILCs from NIP45−/− mice. As 
mentioned above, we demonstrated that NIP45−/− mice have a reduced number of ILC2s and a decreased expression 
of ST2 after allergen sensitization and challenge. Therefore, we wanted to further analyze the differentiation of ILC2s 
in the absence of NIP45. Thus, we isolated bone marrow cells from wild-type and NIP45−/− mice and depleted lineage 
Figure 5. Decreased Th2 cytokine production and ILC2 numbers in the lungs of allergen sensitized and 
challenged Nip45−/− mice. (a–c) Concentration of IL-4 (a), IL-5 (b) and IL-13 (c) in the supernatants of α-CD3/
CD28 antibodies stimulated total lung cells isolated from Nip45−/− and wild-type control mice after allergen 
sensitization and challenge measured via ELISA. One representative experiment is shown with three to four 
mice per group. (d) Expression of St2 mRNA in lung tissue of healthy and asthmatic wild-type and Nip45−/− 
mice analyzed via qPCR. (e) Flow cytometry analysis of Lin-Thy1.2+ cells in total lung cells isolated from wild-
type and Nip45−/− mice after induction of asthma. (f,g) Analysis of Lin- ST2+ (f) and Lin- Thy1.2+ KLRG1+ 
ICOS+ ILC2s (g). n = 3–5 mice per group. Statistical significances in this figure were evaluated with a Students t 
test. * P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Data are mean ± s.e.m.
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positive cells. The lineage negative cells (about 90% purity as shown in Fig. 8f) were cultured for five days with medium 
alone or with IL-2 and IL-33 (Fig. 8f–l). We then measured some ILC2 lineage specific genes via qPCR. First, we inves-
tigated St2 mRNA expression and found that ST2 is induced after 5 days of culture with IL 33 and IL-2 in both wild-type 
and NIP45−/− cells, but the knockout cells expressed significantly lower levels of ST2 mRNA (Fig. 8g). Additionally, we 
investigated the expression of the ILC2 signature transcription factor RORα and found that Rora mRNA is significantly 
increased in the stimulated wild-type cells, but not in the NIP45−/− bone marrow derived ILC2 cells (Fig. 8h). Two 
other ILC2 markers were analyzed at RNA level, namely the transcription factor GATA3 and the IL-2R alpha chain 
(CD25). Both genes were significantly induced after IL-33 and IL-2 stimulation in wild-type as well as NIP45−/− cells 
(Fig. 8i,j). NIP45−/− cells expressed significantly lower levels of GATA3 and CD25 mRNA than wild-type cells. Since 
ILC2s are known to produce high amounts of the Th2 cytokines IL-13 and IL-5, we aimed to investigate their produc-
tion on mRNA and protein level. We observed that both cytokines were significantly induced after stimulation with 
IL-33 and IL-2 in both wild-type and NIP45−/− cells at protein level. Furthermore, we found that NIP45−/− cells had a 
significantly less IL-5 and IL-13 compared to wild-type cells (Fig. 8k,l). Thus, these results further suggest that NIP45 
plays an important role in the differentiation of ILC2s.
Discussion
In the present study, we demonstrate that asthmatic pre-school children at the age of 4–6 years as well as adult 
asthmatics have a significantly increased expression of NIP45 in the peripheral blood, compared to healthy chil-
dren and adults, indicating that NIP45 plays an important role in the pathogenesis of asthma. In support of this 
hypothesis, we showed in two murine experimental models of allergic asthma that NIP45−/− mice do not develop 
the classical characteristics of allergic asthma, such as AHR, inflammation in the lung, mucus production and 
local eosinophil influx. We also found that NIP45 deficiency led to a significant decrease of the Th2 cytokines 
Figure 6. Reversed asthmatic phenotype in Nip45−/− mice after local administration of recombinant IL-33 
in a murine model of asthma. (a) Experimental design of the murine asthma model with administration of 
1 µg rIL-33 on day 14, 30 minutes before the allergen challenge. (b) Airway resistance to increasing doses of 
methacholine was measured in allergen sensitized and challenged Nip45−/− mice and control mice by non-
invasive plethysmography. Airway resistance was analyzed as Penh. One representative experiment is shown 
with three to five mice per group. (c) Pathological score of the inflammation in the lungs of asthmatic Nip45−/− 
mice and control mice with or without additional rIL-33 treatment and corresponding pictures of the H&E 
staining. (d) Periodic acid-Shiff (PAS) staining of lung sections from asthmatic and rIL-33 treated Nip45−/− 
mice and control mice. (e–g) Protein levels of (e) IL-4, (f) IL-5 and (g) IL-13 in asthmatic Nip45−/− mice treated 
additionally with rIL-33. (h) Expression of St2 mRNA in lung tissue of asthmatic Nip45−/− and control mice 
with and without rIL-33 treatment via qPCR. n = 3 to 9 mice per group. Student’s t test was used to calculate 
statistical significances. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Data are expressed as mean ± s.e.m.
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IL-4, IL-5 and IL-13, which are the principle components in the onset of asthma. NIP45 usually coordinates 
the NFAT-driven Th2 cytokine-expression responses3–5. Targeted deletion of NIP45 seems to be sufficient to 
down-regulate the expression profile of Th2 cells in asthma. ILC2s are innate-like cells, which are known to be 
potent producers of the Th2 cytokines IL-5 and IL-1340. These mediators increase after allergen exposure and 
therefore play an important role in the pathogenesis of asthma28,30,31. They can be induced via the IL-1 family 
cytokine IL-33, an alarmin which is highly expressed in the lung by damaged epithelial cells. IL-33 acts through 
the IL-1 receptor-related protein ST2, an orphan member of the IL-1 receptor family, which is expressed on 
ILC2s31,32,41. In this study we showed that asthmatic NIP45−/− mice displayed a reduced number of ILC2s due 
to their increased apoptosis and decreased proliferation rate. This intrinsic property of ILC2s lacking NIP45 
probably has an impact on the protective phenotype observed in NIP45−/− mice with reduced allergic asthma, 
potentially caused by the downstream NFAT-mediated reduction of Th2 cells that is dependent on the decreased 
number of ILC2s. To prove this hypothesis, we treated intranasally wild type and NIP45−/− mice with recom-
binant IL-33 in our murine model of asthma. Treating the NIP45−/− mice with rIL-33 reversed the protective 
asthmatic phenotype found in NIP45 deficiency. These mice now displayed a significant increase in AHR, lung 
inflammation and mucus production. Additionally, the asthmatic NIP45−/− mice treated with rIL-33, had signif-
icantly elevated levels of IL-5 in the lung, indicating an effect of IL-33 on eosinophil development independent 
from NIP45. We also demonstrated that rIL-33 induced the transcription of the mRNA of its receptor ST2 in our 
model of allergic asthma, at least in the absence of NIP45. These results indicate how important IL-33 and ILC2s 
are in the outcome of allergic asthma, especially in the absence of NIP45. By looking further into the mechanism 
of ILC2 differentiation in NIP45−/− and wild type mice, we intravenously injected a microcircle DNA vector 
Figure 7. Inhibition of the asthmatic phenotype in Nip45−/− mice in a HDM-induced asthma model. (a) 
Experimental design of the HDM-induced asthma model. (b) Flow cytometric analysis of lung GATA3+ 
KLRG1+ Thy1.2+ Lin- ILC2s in HDM-treated wt mice and GATA3+ Thy1.2+ Lin- ILC2s in HDM-treated 
wt and Nip45−/− mice. n = 2 to 7 mice per group in two independent experiments (green and blue dots 
differentiate the groups from two separate experiments). (c) Airway resistance was measured as Penh with a 
whole-body plethysmograph to rising doses of the broncho-constrictor Methacholine. (d) Lung sections of 
untreated and HDM-treated Nip45−/− and wild-type control mice were stained for Periodic acid-Shiff (PAS) 
to show mucus producing cells in purple. (e) Percentage of CD4+ GATA3+ T cells in the lungs of Nip45−/− 
and wild-type control mice analysed via flow cytometry. (f) Protein concentration of IL-4 in total lung cells 
stimulated with HDM for 24 h measured via ELISA. Student’s t test was used to evaluate statistical significances 
(c–f). Mann-Whitney U test was used to calculate significances in (b). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Data 
are expressed as mean ± s.e.m.
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expressing IL-25 in vivo and looked at spleen derived ILC2 differentiation. We found that NIP45−/− ILC2s differ-
entiated less and underwent apoptosis more frequently. Furthermore they proliferated less and produced less Th2 
cytokines as compared to ILC2s isolated from the wild type littermates.
Thus, our data suggest that NIP45 not only plays a crucial role in the differentiation of Th2 cells but also in the differ-
entiation of ILC2s in allergic asthma, because it is able to induce IL-4 as well as IL-13. In fact, in allergic asthma patients, 
inhibiting NIP45 might result in a reduction of Th2 cells and ILC2s, accompanied by a reduced asthmatic phenotype.
Although additional experiments, like adoptive transfer of ILC2 from wild type and NIP45 deficient mice KO 
cells should be performed in RAG KO to study asthmatic phenotype by cytokine administration like IL-33 and/
or IL25, targeting NIP45 emerges as a potentially novel approach for suppression of ILC2 cells and Th2 cytokine 
production in asthma.
Materials and Methods
All methods described in this manuscript were carried out in accordance with relevant guidelines and regula-
tions. All experimental protocols were approved by a named institutional and/or licensing committee/s, including 
any relevant details.
Human studies. In the human studies reported in this manuscript, informed consent was obtained from all 
subjects or, if subjects are under 18, from a parent and/or legal guardian.
Figure 8. Reduced ILC2 number and specific markers and cytokine in the absence of Nip45. (a) Mice were 
hydrodynamically injected with DNA vectors encoding for Il25 or Il33 or left untreated. Lung cells were isolated 
after five days and nILC2s (lin− CD127+ KLRG1int ST2+) and iILC2s (lin− CD127+ KLRG1hi ST2−) analyzed. 
(b) Experimental design for ILC2 enrichment and sorting from the spleens of wt and NIP45−/− mice treated 
in vivo with microcircle DNA expressing IL-25. (c) Cell count of wt and Nip45−/− ILC2s during the expansion 
phase (day 0 to 11). (d) IL-4 protein concentration was measured in the supernatants of cultured ILC2 
collected at day 8 and 11 during the expansion phase. (e) mRNA expression of Nip45 measured via qPCR in 
wt and Nip45−/− ILC2s cultured for 14 days and restimulated with IL-2 for 24 h. (f) Experimental design of the 
differentiation of ILC2 from the bone marrow. Lineage negative cells were magnetically sorted the bone marrow 
of wt and Nip45−/− mice and cultured for 5 days in medium. Afterwards RNA was extracted and an pPCR was 
performed. (g–l) qPCR analysis of different ILC2 markers, (g) St2, (h) RORa, (i) Gata3, and (j) Cd25. Protein 
levels of (k) IL-5 and (l) IL-13 were measured in the cell supernatants by ELISA. One representative experiment 
is shown with n = 4 mice per group. Statistical significances in this figure were evaluated with a Students t test 
and Mann-Whitney U test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Data are mean ± s.e.m.
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cohort of pre-school children and isolation of pBMcs. In the European Study PreDicta 
(Post-infectious reprogramming and its association with persistence and chronicity of respiratory allergic dis-
eases). We examined healthy and asthmatic pre-school children at the age of 4–6 years in collaboration with the 
children hospital in Erlangen. This cohort has been described elsewhere42,43. All the experiments with human 
samples were approved by the Ethics Committee of the Friedrich-Alexander University Erlangen-Nürnberg, 
Germany under the approval number ‘Re.-No. 4435 and is registered in the German Clinical Trials Register 
(www.germanctr.de: DRKS00004914). Furthermore, unstimulated PBMCs were isolated from the blood of the 
children and analyzed for gene expression.
Heparinized blood was transferred to a 15 ml sterile tube and diluted with an equal volume of PBS, inverted 
and carefully stratified on Ficoll-Hypaque. The peripheral blood mononuclear cells (PBMCs) were isolated and 
mRNA was extracted by using PeqGold RNA Pure according to the manufacturer’s protocol (PeqLab, Erlangen, 
Germany) or with an AllPrep DNA/RNA Mini Kit (Quiagen, Hilden, Germany). Quantitative real time PCR was 
performed as described below.
Isolation of human CD4+ t cells from a cohort of asthmatic and control adults. Asthma 
Bio-Repository for Integrative Genomic Exploration (ABRIDGE) is an open-access biorepository for subjects 
participating in genetic studies of asthma in the EVE Consortium44.
Sample collection and processing of CD4+ T lymphocytes were carried out at each institution according to 
standardized and validated protocols. These samples were centralized at the Data Coordinating Center at the 
Channing Division of Network Medicine at Brigham and Women’s Hospital for the assembly of Asthma BRIDGE. 
This study was approved by local Ethic committee as previously reported. Contributing centers isolating periph-
eral blood CD4+ T lymphocytes used a modified version of the protocol previously optimized for collections 
in the CAMP study using Miltenyi Biotec anti-CD4+ microbeads and column separation. The modification 
includes isolating peripheral blood mononuclear cells (PBMCs), and then stimulating with phytohemagglutinin 
(PHA) prior to CD4+ lymphocyte isolation.
Mice. The wild-type and Nip45−/− mice (the latter being a generous gift from Prof Laurie Glimcher 
and Karen Mowen) had a Balb/c genetic background. Wild-type and Nip45−/− mice used for the invasive 
body-plethysmograph had a C57BL/6 genetic background. The experiments were performed with mice aged 6–8 
weeks. The animals were bred in individually ventilated cages at the animal facility adjacent to our institute and 
had free access to food and water. All experiments were performed with approved licenses (23-177-07/G09-1-008 
from ethical review board Rheinland-Pfalz and 54-2532.1-2/10 and 54-2532.1-55/12 from the government of 
Mittelfranken, Bavaria).
oVA sensitization and challenge. Wild-type mice and Nip45−/− mice received an intraperitoneal 
injection of 100 µg OVA (Calbiochem, San Diego, CA) complexed with 10% alum (Sigma Aldrich, Steinheim, 
Germany) on days 0 and 7. On the days 16, 17 and 18 the animals were intranasally treated with OVA or PBS 
(2 mg OVA/ml PBS in solution). The airway hyperresponsiveness was measured on day 18. In a second asthma 
protocol mice were sensitized with OVA/Alum and challenged with OVA or sensitized with PBS/Alum and chal-
lenged with PBS. The animals were sacrificed on day 18 to isolate lung cells as described below. To measure airway 
reactivity, we used a non-invasive whole-body plethysmography performed with a Buxco Electronics apparatus. 
Airway hyperresponsiveness was analyzed as Penh. Additonally, AHR was measured invasively by using a body 
plethysmograph (Buxco Electronics, Inc., Wilmington, NC) as previously reported45.
HDM treatment. Wild type and Nip45−/− mice were treated intranasally with saline or 100 µg HDM protein 
obtained from Dermatophagoides pteronyssinus whole body extract (Greer Laboratories, Lenoir, NC) in a volume 
of 50 µl saline on day 0. Additionally, the mice received intranasally 10 µg HDM extract or PBS on 5 consecutive 
days (day 7–11). Airway hyperresponsiveness was measured 24 h after the last intranasal HDM application. On 
day 13, lung cells were isolated as described below.
collection and analysis of the BAL. Bronchoalveolar lavage was performed 24 h after the last allergen 
challenge, by intratracheally injecting and aspirating 0.8 ml saline twice. After its collection the BALF was centri-
fuged for 5 min at 1500 rpm.
The cell pellets were resuspended in 1 ml PBS and an aliquot was stained with trypan blue solution and cells 
were counted using a Neubauer chamber. Eosinophils and neutrophils were detected by fluorescence-activated 
cell sorting (FACS) analysis. The cell surface staining was performed with antibodies against CD3 (eBioscience, 
Frankfurt, Germany), GR-1 (BD Bioscience, Heidelberg, Germany), CD45R (eBioscience, Frankfurt, Germany) 
and CCR3 (BD Bioscience, Heidelberg, Germany) for 30 min at 4 °C. The samples were analyzed by using a 
FACS-Calibur or LSR-Fortessa (BD Bioscience, Heidelberg, Germany) and FlowJo (Treestar Inc).
Histological analysis. Lung tissues were analyzed by using paraffin-embedded tissue slices for histology. 
After staining with Hematoxylin/Eosin, the pathologist performed a blind analysis of the peribronchial and 
perivascular inflammation, by using a semi-quantitative scoring system with a range pending between 1 (mild) 
and 4 (severe) as described before33. Additionally, to investigate mucus production, Periodic Acid-Schiff (PAS) 
staining was performed on paraffin-embedded lung tissue sections
eLiSA. Mouse IL-4, IFN-gamma and IL-5 were detected by using OptEIA™ sandwich ELISA kits from BD 
Bioscience (Heidelberg, Germany). Mouse IL-13 was detected by using a Duoset™ sandwich ELISA kit from 
R&D Systems (Wiesbaden, Germany).
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RnA isolation and quantitative real time–pcR. Total lung tissue was homogenized and total 
RNA from the tissue, total lung cells, sorted ILC2s or bone marrow cells or spleen was then extracted by using 
PeqGold RNA Pure according to the manufacturer’s protocol (PeqLab, Erlangen, Germany). RNA (1 µg) was 
reverse transcribed using the first strand cDNA synthesis kit for RT-PCR (MBI Fermentas, Sat. Leon-Rot, 
Germany). The resulting template-cDNA was amplified by quantitative real-time PCR using SsoFast EvaGreen 
Supermix (Bio-Rad Laboratories, München, Germany). The qPCR was performed with a cycle of 2 min 
98 °C, 50 cycles at 5 s 95 °C, 10 s 60 °C, followed by 5 s 65 °C and 5 s 95 °C in a CFX96 Touch Real-Time PCR 
Detection System (Bio-Rad Laboratories, München, Germany). The primers and sequences used for mouse 
were as follows: St2 (5′-GCGGAGAATGGAACCAACTA-3′, 5′-AAGCAAGCTGAACAGGCAAT-3′), 
Rora  (5 ′ -TCTC C CTGC GCTCTC C GCAC-3 ′ ,  5 ′ -TC CACAGATCT TGCATGGA-3 ′ ) ,  G ata3 
(5′-GTCATCCCTGAGCCACATCT-3′, 5′-TAGAAGGGGTCGGAGGAACT-3′), Cd25 (5′-GCTCACC 
TGGCAACACAGATGG-3′, 5′-GGAAACAGCCGTTAGGTGAATGCT-3′), T-bet (5′-CCT GGA CCC AAC 
TGT CAA CT-3′, 5′-AAC TGT GTT CCC GAG GTG TC-3′) and Nip45 (5′-AGGGACAAAAGCAGAAAGCA-3′, 
5′-CATCCTGACAGGCAGTCTCA-3′). The mRNA of the genes of interest was normalized using the mRNA levels 
of the housekeeping gene Hprt (5′-GCCCCAAAATGGTTAAGGTT-3′, 5′-TTGCGCTCATCTTAGGCTTT-3′). For 
human analysis the following primers and sequences were used: hHPRT (5′-TGACACTGGCAAAACAATGCA-3′, 
5′-GGTCCTTTTCACCAGCAAGCT-3′), hNIP45 (5′-AGTTCTCCAGAGGCCACAGA-3′, 5′-TCAATGAGG 
TCCCCAGAT TC-3 ′ ) ,  NFATc1  (5 ′-GCATCACAGGGAAGACCGTGTC-3 ′ ,  5 ′-GAAGT TCAA 
TGTCGGAGTTTCTGAG-3′) and T-bet (5′-CCC TTG GTG TGG ACT GAG AT-3′, 5′-GTC GGT GTC CTC CAA 
CCT AA-3′.
flow cytometry analysis and intracellular staining. Total lung cells were stained with anti-CD4 and 
anti-CD8 (BD Bioscience, Heidelberg, Germany), anti-CD3, anti-CD11b, anti-CD11c, anti-CD19 and anti-FcεRI 
(eBioscience, Frankfurt, Germany), or anti-ST2 (MD bioscience GmbH, Egg b. Zürich, Switzerland) antibodies 
for 30 min at 4 °C and washed once before measuring. For intracellular staining the cells were fixed with fixa-
tion/permeabilization solution (eBioscience, Frankfurt, Germany) for 35 min at 4 °C and then stained with an 
antibody against GATA3 (BD Bioscience, Heidelberg, Germany) for 30 min at 4 °C in permeabilization buffer. 
Afterwards cells were washed once with permeabilization buffer (eBioscience, Frankfurt, Germany) and finally 
with PBS. For ILC2 staining, a premixed lineage cocktail (Miltenyi Biotec) containing biotinylated anti-CD3, 
anti-CD5, anti-CD11b, anti-CD11c, anti-B220, anti-NK1.1, anti-Ter-119, anti-Gr1, and anti-Siglec-F monoclonal 
antibodies was used. Streptavidin conjugated to Brilliant Violet 421 (BioLegend) was applied in a secondary stain-
ing. The following fluorochrome-tagged antibodies for surface staining were purchased from Miltenyi Biotech, 
unless specified otherwise: anti-Thy1.2 (30-H12), anti-KLRG1 (2F1), anti-ICOS (7E.17G9), anti-ST2 (DJ8, MD 
bioscience), anti-CD11b (M1/70, Invitrogen), anti-SiglecF (ES22-10D8), anti-Gr1 (1A8, BioLegend), anti-CD11c 
(N418, Invitrogen). The samples were analyzed by using a FACS-Calibur or LSR-Fortessa (BD Bioscience, 
Heidelberg, Germany) and FlowJo (Treestar Inc).
ILC2 expansion in vivo, isolation and in vitro expansion. To expand ILC2s in vivo, mice were injected 
intravenously with 6 µg of a minicircle DNA vector expressing IL-25 as previously described46. Subsequently, 
single cell suspensions from spleen and mesenteric lymph nodes were prepared using the gentleMACS Octo 
device (Miltenyi Biotec) according to the manufacturer’s instructions. ILC2s were identified using the fol-
lowing sort panel: ICOS VioBlue+ (7E.17G9, Miltenyi Biotec), KLRG1 PE+ (REA1016, Miltenyi Biotec), CD5 
FITC− (REA421, Miltenyi Biotec), CD45R FITC− (REA755, Miltenyi Biotec), NKp46 FITC− (REA815, Miltenyi 
Biotec), CD49b PE-Vio770− (REA981, Miltenyi Biotec), CD11b APC-Vio770− (REA592, Miltenyi Biotec), 
CD11c APC-Vio770− (N418, Miltenyi Biotec), CD3 FITC− (17A2, BioLegend) and FcεR1a PE-Cy7− (MAR-
1, Invitrogen). FACS purification was achieved by using a MoFlo Astrios EQ device (Beckman Coulter) at 
the Core Unit Cell Sorting Erlangen. Subsequently, ILC2s were expanded in vitro for 11 days by cell culture 
in DMEM GlutaMAX medium supplemented with 10% FBS, 1x MEM NEA (Gibco), 1 mM sodium pyruvate 
(Gibco), 20 mM Hepes (Carl Roth), 50 µM 2-Mercaptoethanol (Sigma-Aldrich), 1% Penicillin-Streptomycin 
(Sigma-Aldrich) and recombinant IL-7, IL-25, IL-33 (50 ng/ml each, Immunotools), IL-2 (50 ng/ml, BioLegend) 
and TSLP (20 ng/ml, Invitrogen). Thereafter, ILC2s were restimulated in cell culture medium supplemented 
with IL-2 and IL-7 (10 ng/ml) for at least 48 h before re-stimulation with IL-2 for 24 hours. For flow cytometric 
analyses, the following fluorochrome-tagged antibodies were used for cell surface staining: anti-CD4 (RM4-5, 
BD Biosciences) and anti-CD45 (30F11, Miltenyi). For intracellular cytokine stainings, cells were stimulated for 
4 hours with the Cell Stimulation Cocktail plus protein transport inhibitors (Invitrogen) prior to surface stainings. 
Depending on the experiment, cells were subsequently fixed and permeabilized using the Foxp3 Transcription 
Factor Staining Buffer Kit (Invitrogen) according to manufacturer’s instructions followed by intracellular stain-
ing with fluorochrome-coupled anti-GATA3 (REA174, Miltenyi Biotec), anti-IL-13 (eBio13A, eBioscience) or 
anti-Ki-67 (16A8, BioLegend) antibodies. Apoptosis was investigated using the Annexin V Kit with propidium 
Iodide (PI; Miltenyi Biotec) according to manufacturer’s instructions. The samples were analyzed by using a FACS 
Canto II cell analyzer (BD Bioscience, Heidelberg, Germany) and FlowJo (Treestar Inc).
ILC2 differentiation from the bone marrow. Hind legs of the mice were prepared and bone marrow 
cells were flushed from the tibias and femurs with sterile PBS. Cells were then centrifuged for 5 min at 4 °C and 
1500 rpm and resuspended in RPMI 1640 culture medium supplemented with 10% FBS, 1% penicillin/strepto-
mycin, 1% L-Glutamin and 50 µmol β-mercaptoethanol. Afterwards, lineage positive cells were depleted with a 
Lineage cell depletion kit from Miltenyi Biotec (Bergisch Gladbach, Germany) according to the manufacturer’s 
instructions. Purity of the cells was measured by flow cytometry with an anti-Biotin antibody conjugated with 
APC and 20 min incubation. Then, cells were cultured for 5 days at a density of 1 × 106 cells/2 ml medium alone 
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or medium with 10 ng/ml recombinant IL-33 (ImmunoTools, Friesoythe, Germany) and 10 ng/ml recombinant 
IL-2 (ImmunoTools, Friesoythe, Germany). Supernatants were collected and analysed by ELISA and RNA was 
extracted from cell pellets as mentioned above.
Statistical analysis. Statistical differences were evaluated for significance (P < 0.05) by the Student’s 
two-tailed t test for parametric data. Additionally, we used the Mann-Whitney U test to calculate statistical signif-
icances. Data are given as mean values ± s.e.m.
Gene expression analysis in the subjects from Asthma BRIDGE biorepository was done in R using 
Bioconductor limma package. A linear model was fitted to the expression values for each probe to assess the sig-
nificance of differential expression between adult asthmatics and healthy controls with the inclusion of potential 
confounders. An Empirical Bayes method using eBays function was used to obtain moderated t-statistics for 
NIP4547.
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